financetom
Business
financetom
/
Business
/
Couche-Tard sees clear path to regulatory approval for Seven & i takeover
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Couche-Tard sees clear path to regulatory approval for Seven & i takeover
Mar 10, 2025 6:06 PM

TOKYO (Reuters) - Canada's Alimentation Couche-Tard ( ANCTF ) said on Tuesday it is confident in attaining the U.S. regulatory approvals required to buy out Japan's Seven & i Holdings ( SVNDF ) after the latter said antitrust law would be a barrier to any deal.

Couche-Tard also said it was frustrated by Seven & i's ( SVNDF ) limited engagement, although the two have begun working together on a plan to offload U.S. stores so as to gain regulatory approval.

The comments are the latest salvo in what would be Japan's largest foreign buyout in history, and contradict Seven & i's ( SVNDF ) newly appointed CEO Stephen Dacus, who has reiterated that significant regulatory hurdles stand in the way of a merger.

Seven & i ( SVNDF ) did not immediately respond to a request for comment.

The companies are the top two players in the U.S. convenience-store market, with about 20,000 locations between them.

Couche-Tard said it had identified a portfolio of U.S. stores to potentially offload and had begun talks with prospective buyers at the behest of Seven & i ( SVNDF ).

The Canadian suitor submitted a revised non-binding proposal in January, but had not been permitted to commence due diligence which would allow it to enhance its bid, Couche-Tard said.

"We have reiterated several times over the past few months that we intend to be friendly and persistent in pursuing a transaction," Couche-Tard said.

"We have done that in the face of significant frustration and distraction."

Couche-Tard, which operates the Circle-K chain of convenience stores, has a long record of acquisitions and said it planned to finance the buyout with a combination of equity and debt.

It added that it had received letters from Goldman Sachs, Royal Bank of Canada, and Scotiabank in support of its financing, which would be sized to maintain its strong investment-grade credit rating.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Plus Therapeutics (PSTV) Shares Are Exploding Higher
Why Plus Therapeutics (PSTV) Shares Are Exploding Higher
Mar 20, 2025
Plus Therapeutics Inc ( PSTV ) shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset. What To Know: Plus Therapeutics ( PSTV ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers, announced that the U.S. Food and Drug...
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Mar 20, 2025
* Lively says Baldoni 'weaponizing' defamation case * 'It Ends With Us' co-stars allege competing smear campaigns * Baldoni's lawyers not immediately available for comment (Recasts first paragraph; adds details from Lively court filing, lawyers' comments, paragraphs 2-3, 11-15) By Jonathan Stempel NEW YORK, March 20 (Reuters) - Actress Blake Lively asked a U.S. judge on Thursday to dismiss actor...
What's Going On With Madison Square Garden Stock Thursday?
What's Going On With Madison Square Garden Stock Thursday?
Mar 20, 2025
Madison Square Garden Sports Corp. ( MSGS ) stock is trading higher on Thursday after the Boston Celtics were sold for $6.1 billion, raising the bar for NBA team valuations. What to Know: A group led by William Chisholm and supported by the private equity firm Sixth Street is set to acquire the Boston Celtics for $6.1 billion, according to...
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Mar 20, 2025
Monte Rosa Therapeutics Inc ( GLUE ). on Thursday revealed clinical results from its MRT-6160 Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study. The study objectives were to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, including VAV1 degradation and its impact on T and B cell function following ex vivo stimulation. Results demonstrated sustained, dose-dependent VAV1 degradation of greater than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved